Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 19/20 | 0.86 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.81 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692049 | 1.00 | PTGER4 (0.86) | PTGER4PTGER2MAPK8 | |
| SCHEMBL691838 | 0.92 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL19713765 | 0.92 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL5362948 | 0.91 | PTGER4 (0.81) | PTGER4PTGER2 | |
| SCHEMBL691746 | 0.91 | PTGER4 (0.88) | PTGER4PTGER2MAPK8 | |
| SCHEMBL5359123 | 0.91 | PTGER4 (0.88) | PTGER4PTGER2MAPK8 | |
| SCHEMBL4448244 | 0.91 | PTGER4 (1.00) | PTGER4PTGER2MAPK8 | |
| SCHEMBL19713730 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL120617 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL31049762 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 7/4885MAPK8 1932/4885 |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, EPB41 | PTGER4 1/4885PTGER2 7/4885MAPK8 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.